Product Name Country licenced Alternative Name(s) Geographical rights
Caphosol® Global Global
Caphosol® Dispersible Global Global
Collatamp® Global (excluding USA) Garacoll® (South Africa, Mexico)
Garamycin® Pads (Colombia)
Sulmycin® Implant Schwamm (Austria)
Garamycin® Schwamm (Czech Republic, Liechtenstein, Slovakia, Switzerland)
Duracoll® Implant (Belgium, Luxemburg)
Sulmycin® Implant E Schwamm (Germany)
Garacol® Implant (Netherlands)
Cronocol® (Portugal)
Garamycin® (Poland)
Gentacoll® (Denmark, Finland)
Gentacoll® Implant (Iceland)
Global (excluding USA)
Xenazine® Lebanon, France France, French overseas territories (DOM-TOM), Morocco, Tunisia, Algeria, Lebanon
Custodiol® France, Portugal France, Portugal
Fomepizole EUSA PHARMA Belgium, France, Iceland, Austria, Finland, Germany, Luxembourg, Norway, Sweden, Netherlands, Ireland Austria, Belgium, Bosnia and Herzegovina, Bulgaria, China, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Greece, Hungary, Hong Kong, Iceland, India, Ireland, Italy, Korea, Kosovo, Latvia, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Montenegro, Netherlands, Norway, Pakistan, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK
Dinutuximab beta Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK

 

Dinutuximab beta may be available in other countries across the world via a managed access programme.